Skip to main content
Home
  • Solutions
    Clinical solutions
    Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions
    Consulting & Commercial
    Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data
    meeting
    Case studies

    Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

    Innovative research tools showcase
    Technologies

    Technology solutions from early phase through to post-marketing.

  • Sectors
    Sectors

    ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

    Read more
    Biotech Government and Public Health Medical Device Pharmaceuticals
    Biotechnology services navigation panel
    Biotech

    Developing transformative therapies requires a flexible approach.

    Employee engagement program overview
    ICON and You

    Partners making a difference.

  • Therapeutics
    Therapeutics
    Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology
    Cross-therapeutics
    Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health
    Obesity 2025 insights image
    Obesity

    A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

    Biological research visual element
    Therapeutics insights

    ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.

  • Insights
    Insights
    Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel
    banners
    From bottlenecks to breakthroughs

    Human-centred strategies for faster study starts

    More than monitoring whitepaper
    More than monitoring

    How modern monitoring paradigms impact CRA roles

    digital globe network with icons
    Meeting requirements for Joint Clinical Assessments

    A planning guide for health technology developers

  • News & Events
    News & Events

    ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

    Read more
    Press releases In the News Mediakit Awards Events Webinars Social media
    webinar
    When patients lead: Breaking barriers in ultra-rare disease drug development

    3 March 2026. Register today.

    brain
    Boosting clinical trial success in Alzheimer’s, Parkinson’s and other neurodegenerative diseases

    Watch the webinar.

  • About ICON
    About ICON
    Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality
    ICON for
    Patients Volunteers Investigators Jobs & Careers Investors Suppliers
    Responsible business practice indicators
    Sustainability, charity, inclusion and belonging

    ICON Cares is our commitment to making a positive impact on our people, environment and our community.

    Modern reception area at Dublin office
    ICON at a glance

    Delivering successful outcomes across the clinical development lifecycle.

  • Careers
  • Investors
  • Contact
  • 日本語
  • 简体中文
  1. Home
  2. News & Events
  3. Events
  4. Webinars
  5. What's Next in eCOA?

What's Next in eCOA?

Page tools
Share Share
Facebook

Share on Facebook

Facebook

Share on X

Facebook

Share on Linkedin

Bluesky

Share on Bluesky

New insights into equivalence testing methodology and implications for BYOD

  • Date 16 November 2017
    Time 16:00 - 17:00
    Location Webinar
    Timezone Europe/London

On-Demand Webinar Archive

To access the archived recording of this webinar, visit our webinar channel and complete a one time only form. This will give you access to our entire library of archived webinars.

Access Webinar Archive

Overview

In this webinar, we review the accumulating evidence to support measurement equivalence of instruments when migrated to ePRO. We review meta analyses of published quantitative equivalence studies, and a newly published meta synthesis of unpublished cognitive interview studies on over 100 instruments performed by ICON.

These meta analyses provide strong evidence that the measurement properties of instrument migrations that follow ePRO design best practice are unaffected by migration from paper to electronic formats, and provide greater insights to the definition of migration best practice.

While this provides support for the use of bring your own device (BYOD) where instrument properties on mobile device models cannot be tested a priori, we also present new results from the industry’s first definitive BYOD quantitative equivalence study, where we assessed instrument measurement properties between paper, BYOD and provisioned devices. We will propose how the results of this study can be generalized to provide support for the use of BYOD in regulatory submission studies.

Because many PRO instruments were developed and validated on paper, care is needed when migrating them to electronic formats (ePRO) to ensure the measurement properties of the instrument are unchanged, and that the electronic version is easy to use in the target group of patients.

In 2009, the ISPOR ePRO Good Research Practices Task Force published recommendations on the evidence needed to support measurement equivalence when migrating from paper to electronic formats, which included cognitive interview and usability testing (minor modifications due to migration) and quantitative equivalence studies (moderate changes).

These recommendations have been largely adopted by the industry and regulators. However, over the 8 years since their publication, accumulating evidence has indicated that instrument measurement properties are generally well conserved when instruments are migrated to electronic forms where ePRO design best practice is followed. Does this mean that a qualitative or quantitative study may not always be needed when implementing ePRO?

Target audience

  • Professionals working in the field of Outcomes Research e.g. PRO, ePRO, eCOA, COA.
  • Pharmaceutical clinical development.
  • All instrument authors and license holders 
In this section
In this section
  • Press releases
  • In the News
  • Mediakit
    • Facts and figures
    • ICON spokespeople
  • Awards
  • Events
    • Industry events
    • Webinars
    • Workshops
  • Webinars
  • Social media

Connect with us

  • Contact us
  • Submit proposal request
  • Update Email Preferences
  • Global office locator
  • ICON on social media
Site Branding
    ICON plc
  • Contact
  • About ICON
  • Results & Reports
For Clients
  • Therapeutics
  • Solutions
  • Insights
  • Technologies
  • Content preferences
  • Office locations
ICON for
  • Patients
  • Volunteers
  • Investigators
  • Jobs & Careers
  • Investors
  • Suppliers
News & Events
  • Press releases
  • Mediakit
  • Events
  • Webinars
Socials
  • Linkedin
  • Facebook
  • Instagram
  • Youtube

Legal Footer

  • © 2026 ICON plc
  • Disclaimer
  • Privacy & Data
  • Cookies
How can we help?
  • All
  • Website
Popular search terms:
  • Biotech
  • Cell and Gene Therapies
  • Consulting
  • Early Clinical
  • Medical Device
  • Oncology
  • Rare & Orphan Diseases
  • Real World Evidence
  • Site & Patient Recruitment
  • Strategic Solutions
  • Regulatory Intelligence